BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22058422)

  • 1. TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo.
    Puig M; Tosh KW; Schramm LM; Grajkowska LT; Kirschman KD; Tami C; Beren J; Rabin RL; Verthelyi D
    J Leukoc Biol; 2012 Jan; 91(1):147-58. PubMed ID: 22058422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
    Butchi NB; Du M; Peterson KE
    Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.
    Birmachu W; Gleason RM; Bulbulian BJ; Riter CL; Vasilakos JP; Lipson KE; Nikolsky Y
    BMC Immunol; 2007 Oct; 8():26. PubMed ID: 17935622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells.
    Petzke MM; Brooks A; Krupna MA; Mordue D; Schwartz I
    J Immunol; 2009 Oct; 183(8):5279-92. PubMed ID: 19794067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of interferon system genes in Atlantic salmon by the imidazoquinoline S-27609, a ligand for Toll-like receptor 7.
    Kileng Ø; Albuquerque A; Robertsen B
    Fish Shellfish Immunol; 2008 May; 24(5):514-22. PubMed ID: 18337121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7.
    Wang Y; Yan S; Yang B; Wang Y; Zhou H; Lian Q; Sun B
    FEBS Lett; 2015 May; 589(12):1322-30. PubMed ID: 25907537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand.
    Marshall JD; Heeke DS; Gesner ML; Livingston B; Van Nest G
    J Leukoc Biol; 2007 Sep; 82(3):497-508. PubMed ID: 17565046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands.
    Forsbach A; Müller C; Montino C; Kritzler A; Nguyen T; Weeratna R; Jurk M; Vollmer J
    J Interferon Cytokine Res; 2012 Jun; 32(6):254-68. PubMed ID: 22540943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.
    Mohamed FE; Al-Jehani RM; Minogue SS; Andreola F; Winstanley A; Olde Damink SW; Habtesion A; Malagó M; Davies N; Luong TV; Dhillon AP; Mookerjee RP; Dhar DK; Jalan R
    Liver Int; 2015 Mar; 35(3):1063-76. PubMed ID: 24990399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.
    Wang J; Lau KY; Jung J; Ravindran P; Barrat FJ
    Eur J Immunol; 2014 Apr; 44(4):1130-6. PubMed ID: 24375473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
    Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    Tao Y; Zhang X; Markovic-Plese S
    J Neuroimmunol; 2016 Sep; 298():181-8. PubMed ID: 27609294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.
    Nündel K; Green NM; Shaffer AL; Moody KL; Busto P; Eilat D; Miyake K; Oropallo MA; Cancro MP; Marshak-Rothstein A
    J Immunol; 2015 Mar; 194(6):2504-12. PubMed ID: 25681333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral protein Viperin promotes Toll-like receptor 7- and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells.
    Saitoh T; Satoh T; Yamamoto N; Uematsu S; Takeuchi O; Kawai T; Akira S
    Immunity; 2011 Mar; 34(3):352-63. PubMed ID: 21435586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The duck toll like receptor 7: genomic organization, expression and function.
    MacDonald MR; Xia J; Smith AL; Magor KE
    Mol Immunol; 2008 Apr; 45(7):2055-61. PubMed ID: 18036663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.
    Wang Y; Abel K; Lantz K; Krieg AM; McChesney MB; Miller CJ
    J Virol; 2005 Nov; 79(22):14355-70. PubMed ID: 16254370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.
    Gotoh K; Tanaka Y; Nishikimi A; Nakamura R; Yamada H; Maeda N; Ishikawa T; Hoshino K; Uruno T; Cao Q; Higashi S; Kawaguchi Y; Enjoji M; Takayanagi R; Kaisho T; Yoshikai Y; Fukui Y
    J Exp Med; 2010 Apr; 207(4):721-30. PubMed ID: 20231379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.